i say consider celgene. buy buy buy. regeneron and isis.ll ahead, are these boots made for galloping? skechers announced a deal to sponsor california chrome. can you imagine that horse walking in skechers? no, it's just a sponsorship. is it time to get in the race with the stock? i'm taking a tour of the new york show rooms with the ceo and cfo of the footwear company, california chrome couldn't be there. stay with cramer. when we arrived at our hotel in new york, the porter was so incredibly careful careless with our bags. and the room they gave us, it was beautiful. a broom closet. but the best part, / worst part, was the shower. my wife drying herself with the egyptian cotton towels, shower curtain defined that whole vacation for her. don't just visit new york. visit tripadvisor new york. with millions of reviews, a visit to tripadvisor makes any destination better. >>> in an environment where retail is becoming incredibly inconsistent with some companies doing spectacularly, others doing horribly, i think we need to look at the one of t

> > absolutely and celgene has this huge cancer pipeline and now in this day and age, cancer seems to be more and more treatable and it's so so important to these companies and if you look at celgene and its peg ratio which is the price you're paying for growth, it's under 1-- same thing for gilead. so a lot of people are struggling out there looking to find value, looking to find some companies that are raising the top line. these companies are right there. so i say to investors out there if you're looking for growth, it's right in front of you and it's less expensive than people think. > > i do tend to think of biotechs as rolaid stocks so investors may need some to handle possible huge sell-offs in the stocks if trials go wrong, matt. > > stay diversified as always and also invests in companies that you have a feel for and like them, for instance if you happen to know a little bit about some of the products like sovaldi the is the blockbuster hepatitis drug of gilead-- get involved with that and i always say invest in what you want to invest in, and these two companies forward pe's

breakthroughs next on caucus new jersey funding for this edition of caucus new jersey has been provided by celgene corporation committed to improving the lives of patients worldwide the healthcare foundation of new jersey founded by the jewish community md advantage insurance company of new jersey investors bank berkeley college health republic insurance of new jersey and by new jersey natural gas proud to support education in our communities promotional support provided by commerce magazine and by the record north jersey's trusted source and northjersey.com [music playing] [music playing] welcome to caucus new jersey i'm steve adubato you know long wait times and decreased availability of donors has led doctors to seek new methods to support a failing heart here to discuss something called ventricular assist device or vads we have joseph shukis is a patient living with a ventriclar assist device vad doctor george batsides who is a chief of cardac surgery at rwj university hospital audrey kleet is a vad coordinator at morristown medical center and finally sharon holman is a senior occupational the

next on caucus new jersey funding for this edition of caucus new jersey has been provided by celgene corporation committed to improving the lives of patients worldwide the healthcare foundation of new jersey founded by the jewish community md advantage insurance company of new jersey investors bank berkeley college health republic insurance of new jersey and by new jersey natural gas proud to support education in our communities promotional support provided by commerce magazine and by the record north jersey's trusted source and north jersey.com [music playing] [music playing] welcome to caucus new jersey i'm steve adubato you know over three million people suffer from epilepsy in the united states today a new procedure it's called laser ablasion is giving patients new reason for hope joining us here in the studio to discuss this groundbreaking procedure we have melissa thomas who used laser ablasion to treat her epilepsy doctor shabbar danish is director of neurosurgery at rwj university hospital doctor kimberly palangio is director of neurophysiology at the university of medical ce

out there that still have gap up potential on pipeline develop. 24 the case of celgene, you still have resolution from the patent case to go on here. so there's still several names with upside remaining in the sector. >> good to see you. matt rhoden there from ubs. >>> we're going to focus on the bond marked. we have a two-year note auction this week. rick santelli is tracking the action. what grade are you going to give it? >> as i cipher and cipher, i'll tell you what, we're going to give it a c-minus. this auction was kind of like kissing your sister, it wasn't ugly, wasn't pretty, it is what it is. the ultimate yield 0.5211. so it priced right, but everything was a little weak. by a bid to cover was a little light. 23.1, a little light with 26%, ten auction average, same could be said for directs at 23.3. the dealers, when everything is averaged they roughly take 50%. yes, in this case it was 53.6 to be exact. the short maturity auctions should be more solid than this one. this doesn't paint a good picture for the rest of supply. sue, back to you. >> maybe it's just the beginning o

i think celgene, a lot of people want it to pop. 1.39 to 160. he's a bankable krrk ceo. think this company could earn $16 a share. in english, what i'm saying is i think there's a strong pipeline, many drugs there, and if you own this thing for the next five years rather than the next five days, you're going to make a ton of money. and i'm going to pay you the highest compliment. you have horse sense. [ cheers and applause ] let's take one over here. >> boo-yah, jim. >> boo-yah, chief. >> i'm representing the pope john investment club from sparta, new jersey. >> excellent. excellent! sparta, as we know has bears! you never hear of sparta other than the fact you have bears running around all the time in sparta? is that the deal? >> yes. >> because you know what i think about bears? [ laughter ] >> we were gathering our portfolio together and we wanted to hear your opinion on the stock oracle. >> oracle reports next week. i think oracle's going to do a good job. the reason it's doing well is mark hurd is an extremely competitive guy. yes, larry ellison runs it, but mark hu

close to transformative for celgene. earlier in the year i didn't recognize. they just acquired the drug a few months ago. a pretty in asset. i have an opportunity to see celgene later today and can't wait to get their take on my new opinion here. >> why don't they get credit for the pipeline drugs? they've got a great pipeline in phase ii and in phase 3, phase 1. why do you think they don't get the credit? is it the patent issue and are they going to settle that issue, what everybody is, that's the consensus at this point. >> two questions there. number one, why don't thet get more credit? a really big company, about an $80 billion company. big companies need really big drugs to move the needle and not usually until phase 3. most are in phase 1 and 2. that's wide they're not getting credit. simply the size. company, but an opportunity for long-term investors who want to make a bet on a phase 1 or 2 drug that will be in phase 3 in a few years. crohn's disease should be in fade 3 no later than 2015, possible by the end of this year. >> one of the stocks really

a couple of stocks you have in your portfolio, aflac and celgene. >> yes.en up for a long time. you know, they are the largest underwriter of supplemental insurance and 75% of the businesses are in japan so that tells the story of why it's done. the yen is down 22% over the last year versus the dollar. 25% of aflac's business is in the u.s., and the growth for that supplemental space is looking to be about 7% to 10% of volume growth which bodes well for aflac which has a p multiial of about 9 versus an industry of about 12. nice dividend that's growing and the company is very well managed. managed their way through the toxic debt crisis in europe as well as maintaining their dividend through the crisis so we think the company has good management, it's cheap and the future looks bright. cell fine, on the other hand, was beaten down with the other biotech companies and they are being challenged on one of their key drugs, and we think that they will overcome that challenge. indications are that they will, and the company is 25% -- >> we've got to go guys. >> t

whole and you definitely don't want to miss my interview with him and then we're talking to george celgene about banking now sultan says that the best way to create stability in the banking system is to deregulate it and i counter intuitive but by the way yesterday and in today's big deal i'm joined by our chief political correspondent mr sam sachs sam is sitting down with me and i have to discuss the rise of these children separate servant economists who don't want to miss a moment that it all starts right now. with. our lead story today never put something in e-mail that you wouldn't want the whole wide world to read i'm talking to you morgan stanley now the mudslinging between allergan and valley and pharmaceutical got more intense this week but it was actually bankers at morgan stanley who wound up in the crosshairs true story now allergan released in mails sent by a senior morgan stanley banker which outwardly denigrated belly intimates business strategy now allergan the maker of botox is currently fending off a fifty three billion dollars takeover bid by valley and the man behind the

that's celgene. i think what you have to do is you have to see -- the plot hose your stocks have done against a market in good times and bad, you know, when there's growth and no growth. that's what i do. i actually have looked back using charts, 1989, 1991, 1996, 1998, 2000, 2002, and see how they've done. you've got to do that history if you want to feel confident that you have a secular grower whose numbers don't get cut, versus a cyclical number. a whole chapter about that in "get rich carefully." sonny in illinois. >> caller: hey, jim cramer, a big chicago windy city boo-yah to you. >> sweet. >> caller: hey, jim always taking your advice. keep on with your books. >> just a general question for you. always taking your advise about reading up on fundamentals of the company. listens. as rods now in numbers, strong fundamentals, what would your definition of pullback be? >> 5% to 6%. something that lee cooperman, when he was the research director at goldman, first 5% to 7%, take a hard look. i know

i like celgene.till the cheapest, but looking at 2017 earnings and most people are looking at yesterday. bob in pennsylvania. >> great show and great staff. >> fabulous staff. >> last night, you talked about takeover targets ba based on advantages. >> i think mylan's going to do a deal and every time, i say why didn't i recommend. i typically do not like commodity makers of products. they are low cost producer, but i invite the program anymore. be my guest and that ladies and gentlemen is the conclusion of the lightning round. [ indistinct shouting ] ♪ [ indistinct shouting ] [ male announcer ] time and sales data. split-second stats. [ indistinct shouting ] ♪ it's so close to the options floor... [ indistinct shouting, bell dinging ] ...you'll bust your brain box. ♪ all on thinkorswim from td ameritrade. >>> want to catch a clims in the future of a given industry and you should want to because the clearer view of the future, the better you'll likely to be at picking stocks. then sometimes, you have

celgene is interesting on the health care side. it's going to make up a huge part of our gross domestic product in 5 years. we asked jim cramer what's going to be the biggest health care stock? he thinks celgene is going to cure more diseases in the coming years than any other company out there. so that's why he likes celgene. it does a lot of cancer research. and then ibm. the reason why ibm is still in there, guys, is because it's a tech behemoth. it's going to survive the times. but we also think that they could be a big player, maybe, in cybersecurity. it's not outside the helm of possibility for big blue to take its services computer business, and make it so that it involves cybersecurity. so that's going to be a huge theme in 25 years. we think ibm could be one of those ones that really leads that particular industry 25 years from now. guys. back over to you. >> we -- we were at the at&t. >> mm-hmm. >> we had those gentlemen on talking about the future, and none of them were comfortable going out more than five years. three t

that want quality from point of sale, that's one and good results trying to expand the one market celgenein. >> i would say amgen is cheaper than a month and a half ago for no other reason than the stock came down. probably low earnings, double digits. in the meantime you canning by big pharmamultiple and probably go to 3% yields over the next three years and given the market's prediliction for big stocks. >> i agree. we're talking prostate cancer here. we like the news jmj is giving and i think that sets forth for m medivation going forward. >> steve, what do you have being this is your last update? >> 3-2, my friend. don't shoot the messenger here. the new number for ism is 55.4. a little background. we spoke twice to the ceo of ism, who gave us the 56 number. we reported that number. this ceo now tells us he spoke in error and the number is actually 55.4. i don't know about the underlying details. i suspect they're close to being the same. those numbers were all in line with numbers economists calculated themselves given the seasonal adjustment. they had a computer problem. i don't kno

you should be in the googles, in the celgenes, you should be in stocks that are just, you notice, haine have another tweet -- do you have any good suggestions on people who followsh go read confesses of a street addict, and then tell me if you ever want to trade currency. your answer is you won't. the next tweet qush how much do you have so much energy? its i think some of it is genetics, and some is that i love what you do. another tweed which says -- jim, how does one find out the upgrade and downgrace before the opening bell. thanks. when i started the street, i made sure that all those were in, same game, still there. why not take another tweet. this one says -- what book would you suggest for newblies? one up on wall street by peter lynch, the great portfolio manager at magellan, who just made me a fortune in my i.r.a., that is still the best investment book ever written. stick with cramer. [ male announcer ] the mercedes-benz summer event is here. now get the unmistakable thrill... and the incredible rush... of the mercedes-benz you've always wanted. ♪ but you better get here fas

we mentioned celgene should push up to that 175 level months ago. so there are names that still work in this space regardless of what i think about the broader market. >> let's get a broader flash with dom shue. >> it is moving. vertex up 40%. bristol-myers a much larger company in the after hours trade after it announced it halted a late-staged trial for skin cancer drug because of positive results. now, this particular drug represents a product of their immunooncology department. >> that is the department that tries to remedy cancer by using the bid's own defenses and immune systems. so this is a promising hope-filled part of the market for biopharmaceuticals rather than using radiation or xhalts for cancer, which has been the main stay. this particular stock is now moving because of this news, melanoma, skin cancer. this drug halted positive results. that's why it's moving higherch over to you. >> how do levels look on this, guy? >> it's underformed performed, this stock is probably for good reasons, it trades as a crazy multiple 30 times foreign

names like celgene which jim cramer loves.inks they will cure more companies than any in the next ten years we thought, look at the younger companies when they join, they means they could be hypothetic cal, first of all, it's facebook, right, if there is any company that's come out in the past couple years, that might be facebook, right, a big 76% move here's where it gets more interesting for me, i guess. solar city has come out public, a whopping almost 800% here's another one. it will be a huge part of the gdp. intercept pharmaceuticals, it does a lot of liver disease research and drugs and that kind of stuff they came out 1,500% tins their ipos that's the part. >> dominator, dominating the picks. >> facebook, i think it's equally could be in the dow. >> non-existent. >> maybe. >> cell gynelove. i know jim cramer loves it. the whole space got whacked. they're a biotech name. >> i think there will be a dow in 25 years. >> i think nobody will focus on the dow. >> it's a bummer. >> it won't exist if 25 years, thanks, karen. >>

we got a pop for celgene up 4%. >> i think the stock split announcement helped but this stock has beeng back since early march when it had the precipitous drop with the rest of the space. i think it will push up and take up that 175 all-time high. >> the whole space actually has been under some pressure lately. but trulia, this is not deep enough to jump in yet. >> starbucks, delivering on valuation and growth. i stay long. >> we got to drop facebook down 2%. >> website crashed last night, mel. that's what it said on the site. sorry, something is wrong. it's not as bad as the fail whale that used to come up a lot over in twitter. but nonetheless, the site goes down. people get nervous and some people decide to sell. >> a pop for the story you chose -- with more than 90,000 votes. >> that's crazy! >> zombie pigeons one. a group of geneticists are looking to resurrect the long-extinct passenger pigeon. they'll use museum specimen dna to bring the birds back from the dead. before extinct, the passenger pigeon was the most abundant species on earth. >> what could go wrong with that? >> now

we know biogen, and gilead and, of course, celgene on the breakout. >> buy, buy, buy!onclusion of the lightning round! >>> the lightning round is sponsored by t.d. ameritrade. ♪ [ indistinct shouting ] [ male announcer ] time and sales data. split-second stats. [ indistinct shouting ] ♪ it's so close to the options floor... [ indistinct shouting, bell dinging ] ...you'll bust your brain box. ♪ all on thinkorswim from td ameritrade. all on thinkorswim could help your business didavoid hours of delaynd test caused by slow internet from the phone company? that's enough time to record a memo. idea for sales giveaway. return a call. sign a contract. pick a tie. take a break with mr. duck. practice up for the business trip. fly to florida. win an award. close a deal. hire an intern. and still have time to spare. check your speed. see how fast your internet can be. switch now and add voice and tv for $34.90. comcassiness. built for business. >>> thanks heavens for mario draghi, the head of the european central bank and the man that might finally get europe back on its feet an

steph was pushing me a couple time, look at celgene, gilead, some of these names. i didn't do it.but i've had a good run with the pharmas but missed a huge run in some of the biotechs. >> coming up, julia collins just won 20 straight games in gem ar di, the second best record ever. when she watched off the stage last week, this is the song they played. now she's ready to invest her winnings. ♪ she's got her head in the clouds and she's not backing down ♪ >>> welcome back to "halftime report." i'm margaret brennan. check out smith & nephew. wells fargo says it doesn't think medtronic will look to buy the company, this after the analyst spoke with medtronic's manager company e. medtronic trading is down just under 2%. medtronic ceo omar ishrak will be on "closing bell" at 3:00 p.m. eastern. >> thanks so much. look forward to that. >>> winning one round of "jeopardy!" is impressive but how about running off 20 in a row? that's what our next guest recently did. jew julia collins' streak is the second best ever, won her a whopping $428,000. she is live for us today in chicago. julia, w

. >> we think celgene will hit 200 this year. >> and sandy's other picks were sanchez energy, already up 40% year to date and everbank financial. >> "closing bell" is up next. >>> hi, everybody. happy friday, and welcome to "closing bell." i'm kelly evans down here at the new york stock exchange and bill is back. >> i'm back, at least for one day before the weekend here. we've got the markets trading higher today. in fact, we are suddenly -- we find ourselves on dow 17,000 watch. the market -- the dow was up 86 points at the peak of the day but less than 100 point away from dow 17,000 and amazing when you consider we only crossed 16,000 last november. >> and we've been adding on average, what 2,000 dow points a year since the low. >> march of 2009, we've gained more than 10,000 points in that time on the dow, works out to that amount. >> don't have to get to 17,000 mark for it to be another historic session. another close higher for the dow and s&p 500, they will be new record highs. >> stick with us, all the stats. any number you want we've got it right here for you. speaking of stat

boom bust and these are some of the stories that we're tracking for you today first up george at celgene is on the show now celdran is an advocate for free banking which is something that he says what eliminate the need for private national regulation altogether sounds pretty good to me we're going to hear it from him then we have the end of four on the program now down pat a force that down with earlier today to discuss how did how the wages and the boom bust cycle she had are so tight a little shout out in the u.k. economy now is the u.k. in a boom right now he tells us coming right out and in today's big deal edward harrison and i are discussing the fifteen dollar minimum wage battle and how rock star economist thomas piketty it's been through it all it all starts right now. our lead story home ownership now it's become apparent that it's pretty much impossible to talk about homeownership today without mentioning the housing crisis and sadly its effects are still painfully painfully obvious for many americans now a new report by the haas institute at u.c. berkeley reveals that one thi